In a report released today, Bill Sutherland from Benchmark Co. maintained a Buy rating on Agilon Health, with a price target of $4.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Bill Sutherland has given his Buy rating due to a combination of factors that suggest potential positive developments for Agilon Health in the future. Despite the company’s recent challenges, such as the second quarter miss and the suspension of 2025 guidance, there are strategic initiatives underway that could enhance its long-term prospects.
The implementation of an enhanced data platform is expected to improve forecasting accuracy, which is crucial for managing risk adjustments and cost trends. Additionally, the upcoming Medicare rate announcement and renegotiation of payor contracts are anticipated to stabilize revenue streams and improve clinical outcomes. These factors, coupled with the company’s sufficient cash reserves to support operations through 2026, underpin Sutherland’s optimistic outlook for Agilon Health.
In another report released on July 28, Citi also maintained a Buy rating on the stock with a $3.00 price target.